What is Eikon Therapeutics, Inc. 's cash & equivalents?

Eikon Therapeutics, Inc. (EIKN) reported cash & equivalents of $161.15M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Eikon Therapeutics, Inc. EIKN Cash & Equivalents

Cash & Equivalents at other companies

MYR GroupMYRG

$163.19M+1,398%

RepligenRGEN

$582.65M-16.4%

NNN REITNNN

$4.57M-10.3%

Piper SandlerPIPR

$344.43M+173%

Dave, Inc.DAVE

$133.33M+184%

Travel + LeisureTNL

$456M+24.3%

Other financials

Income statement

See full

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

See full

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

See full

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

See full

Market cap$514.86M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's cash & equivalents?: Eikon Therapeutics, Inc. (EIKN) reported cash & equivalents of $161.15M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.